A Phase Ib, Open-label, Multicenter, Dose- escalation study to evaluate the Safety and Pharmacokinetics of Xmab24306 in combination with Daratumumab in patients with relapsed/refractory Multiple Myeloma.

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Murphy, Nicholas (Chief Investigator (CI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date25/02/22 → 31/12/27
View all
View less

Keywords

  • Malignant Haematology
  • Multiple myeloma
  • Clinical trial